Lack of effect of nifedipine on counterregulatory mechanisms in essential hypertension. 1986

N E Bruun, and H Ibsen, and F Nielsen, and M D Nielsen, and A G Moelbak, and O J Hartling

The influence of long-term nifedipine treatment on body fluid compartments, renal function, the renin-angiotensin system, and the adrenergic system was studied in 18 patients with essential hypertension. A placebo period of 4 weeks was followed by a 6-week dose-titration period. Thereafter, the dose was kept constant for an additional 6 weeks (mean dose, 51 mg/day). As compared with placebo values, diastolic blood pressure decreased approximately 12% during nifedipine treatment. Plasma volume, extracellular fluid volume, and the ratio of plasma to interstitial fluid volume did not change significantly, either in the group as a whole or in a subgroup in which pedal edema developed. Plasma concentrations of epinephrine and norepinephrine increased slightly after 2 weeks of treatment, but they returned to control values after 6 weeks of therapy. Plasma concentrations of renin, angiotensin II, and aldosterone did not change significantly. Glomerular filtration rate and renal clearances of sodium and potassium were unchanged as well. These results indicate that long-term nifedipine treatment does not lead to activation of counterregulatory mechanisms, such as fluid retention or the renin-angiotensin or adrenergic systems. This may well be of importance for the antihypertensive efficacy of nifedipine treatment.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D005260 Female Females
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration

Related Publications

N E Bruun, and H Ibsen, and F Nielsen, and M D Nielsen, and A G Moelbak, and O J Hartling
November 1987, Medicina clinica,
N E Bruun, and H Ibsen, and F Nielsen, and M D Nielsen, and A G Moelbak, and O J Hartling
May 1988, Hypertension (Dallas, Tex. : 1979),
N E Bruun, and H Ibsen, and F Nielsen, and M D Nielsen, and A G Moelbak, and O J Hartling
January 1986, Acta physiologica et pharmacologica latinoamericana : organo de la Asociacion Latinoamericana de Ciencias Fisiologicas y de la Asociacion Latinoamericana de Farmacologia,
N E Bruun, and H Ibsen, and F Nielsen, and M D Nielsen, and A G Moelbak, and O J Hartling
July 1986, International journal of clinical pharmacology, therapy, and toxicology,
N E Bruun, and H Ibsen, and F Nielsen, and M D Nielsen, and A G Moelbak, and O J Hartling
March 1994, Polskie Archiwum Medycyny Wewnetrznej,
N E Bruun, and H Ibsen, and F Nielsen, and M D Nielsen, and A G Moelbak, and O J Hartling
February 1997, Clinical nephrology,
N E Bruun, and H Ibsen, and F Nielsen, and M D Nielsen, and A G Moelbak, and O J Hartling
January 1990, European journal of clinical pharmacology,
N E Bruun, and H Ibsen, and F Nielsen, and M D Nielsen, and A G Moelbak, and O J Hartling
June 1989, Journal of human hypertension,
N E Bruun, and H Ibsen, and F Nielsen, and M D Nielsen, and A G Moelbak, and O J Hartling
June 1990, The American journal of cardiology,
N E Bruun, and H Ibsen, and F Nielsen, and M D Nielsen, and A G Moelbak, and O J Hartling
January 1990, Lijecnicki vjesnik,
Copied contents to your clipboard!